Given that HCC is refractory to almost all forms of chemotherapy, our data suggest that BafA1 alone, or in combination with a JNK inhibitor, may represent a promising therapeutic approach in HCC. This evidence concerns the gene MAPK8 and hepatocellular carcinoma.